Announcements

The Medicines Patent Pool Signs New Round of Generic Manufacturing Licences for HIV and Hepatitis C Treatments

Zydus Cadila joins the MPP as new partner Geneva, 07 July 2016 – The Medicines Patent Pool (MPP) announced new generic manufacturing licences today for four antiretrovirals and hepatitis C direct-acting antiviral daclatasvir. The organisation signed licences with Aurobindo, Desano, Emcure, Hetero Labs, Laurus Labs, Lupin and new partner Zydus … Read more

The Medicines Patent Pool Releases 2015 Annual Report: Five Years of Patent Pooling for Public Health

MPP Reports $195 Million in Savings through Partners’ Supply of Low-Cost Medicines (GENEVA, 26 May 2016) — The Medicines Patent Pool (MPP) released its 2015 Annual Report today reviewing last year’s accomplishments and highlighting its half decade of work in public health-oriented voluntary licensing to improve access to HIV medicines … Read more

ViiV Healthcare, Medicines Patent Pool Extend Licence for Dolutegravir to all Lower Middle-Income Countries

Specifically benefits more than 270,000 people living with HIV in Armenia, Moldova, Morocco and Ukraine   Geneva, 25 April 2016 — The Medicines Patent Pool (MPP) and ViiV Healthcare announced an extension of their current licensing agreement today to increase access to dolutegravir (DTG), a promising new antiretroviral, to cover … Read more

TB Alliance and the Medicines Patent Pool Sign Memorandum of Understanding to Improve Access to TB Medicines in Resource-Limited Nations

  NEW YORK AND GENEVA (April 20, 2016) – TB Alliance and the Medicines Patent Pool (MPP) today announced a Memorandum of Understanding outlining a multi-pronged collaboration to encourage the development of new tuberculosis (TB) regimens and ensure their availability in low-and middle-income countries. The two organisations will work together … Read more

Executive Director Statement on the Appointment of New Chair of the Medicines Patent Pool Governance Board

GENEVA, March 21, 2016 — I am pleased to announce that Sigrun Møgedal has agreed to assume the position of chair of the Medicines Patent Pool (MPP) Governance Board, effective immediately. Sigrun, a long-time member of the Board, takes over the reins from Charles Clift, the founding chair, who served … Read more

The Medicines Patent Pool Signs First Sub-licences for Hepatitis C Medicine Daclatasvir

 Four companies to help speed access to curative direct-acting antiviral in 112 low- and middle-income countries Geneva, 20 January 2016 – The Medicines Patent Pool (MPP) announced its first round of sub-licences for the generic production of Bristol-Myers Squibb’s daclatasvir, a novel direct-acting antiviral that is proven to help cure … Read more

The Medicines Patent Pool and AbbVie Sign Licensing Agreement to Increase Access to Crucial HIV Treatments Throughout Africa

MPP, AbbVie and South African Department of Health work together to establish long-term solutions for antiretroviral therapies (ARVs)   Geneva, 18 December 2015 — The Medicines Patent Pool (MPP) today announced a new licensing agreement with AbbVie, a global biopharmaceutical company, that seeks to address future demands for HIV treatment Lopinavir/Ritonavir (LPV/r) in … Read more

The Medicines Patent Pool welcomes USAID’s selection of two South African organisations to address HIV/AIDS

Geneva, December 11, 2015 –The Medicines Patent Pool welcomes the USAID selection of two leading South African organisations to address the global challenges of HIV treatment announced yesterday in Washington DC and Johannesburg.  One of the new awardees, Wits Reproductive Health Institute, will lead efforts to simplify antiretroviral therapy (ART) as … Read more

The Medicines Patent Pool Signs a Collaborative Agreement with the University of Liverpool to Develop HIV Nanomedicines

Partnership includes an MPP licence for the university’s Solid Drug Nanoparticle (SDN) Technology; Aims to support treatment scale-up through cost cuts of priority antiretrovirals (ARVs) Geneva, 1 December 2015 — The Medicines Patent Pool (MPP) today announced a collaboration with the University of Liverpool and a licence for the university’s Solid Drug … Read more

MPP Statement on WHO Policy Brief: Consolidated Guidelines on the Use of Antiretrovirals (ARV) in the Treatment of HIV

On the eve of World AIDS Day, the Medicines Patent Pool welcomes the publication of the World Health Organization’s policy brief: “Consolidated guidelines on the use of antiretroviral drugs in treating and preventing HIV infection.” The WHO issued the new guideline directions on November 27 for discussion at the International … Read more